• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Argos Therapeutics

edit

Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.

Recent Milestones

edit

• 
  Argos Therapeutics received $25M in Series D funding. (4/24/12)
  Posted 4/24/12 at 5:49pm via argostherapeutics.com
• 
  Argos Therapeutics added Frederick M. Miesowicz as COO.
  Posted 7/29/11 at 7:44pm
• 
  Argos Therapeutics added Jeffrey D. Abbey as President & CEO.
  Posted 7/29/11 at 7:44pm
• 
  Argos Therapeutics added Isaac Cheng as board observer.
  Posted 5/4/13 at 9:19am

Videos

Screenshots

edit

Above: Home Page
Uploaded: 2/17/12

Sources

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012 (argostherapeutics.com) [edit]